These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Wen Z; Ye L; Gao Y; Pan L; Dong K; Bu Z; Compans RW; Yang C Antiviral Res; 2009 Dec; 84(3):215-24. PubMed ID: 19772876 [TBL] [Abstract][Full Text] [Related]
3. Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines. Nogales A; DeDiego ML; Topham DJ; Martínez-Sobrido L J Virol; 2016 Jul; 90(14):6291-6302. PubMed ID: 27122587 [TBL] [Abstract][Full Text] [Related]
4. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Tang XC; Lu HR; Ross TM Viral Immunol; 2011 Aug; 24(4):311-9. PubMed ID: 21830902 [TBL] [Abstract][Full Text] [Related]
5. Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies. Buffin S; Peubez I; Barrière F; Nicolaï MC; Tapia T; Dhir V; Forma E; Sève N; Legastelois I Vaccine; 2019 Oct; 37(46):6857-6867. PubMed ID: 31590935 [TBL] [Abstract][Full Text] [Related]
6. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate. Venereo-Sanchez A; Gilbert R; Simoneau M; Caron A; Chahal P; Chen W; Ansorge S; Li X; Henry O; Kamen A Vaccine; 2016 Jun; 34(29):3371-80. PubMed ID: 27155499 [TBL] [Abstract][Full Text] [Related]
7. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Schmeisser F; Adamo JE; Blumberg B; Friedman R; Muller J; Soto J; Weir JP Vaccine; 2012 May; 30(23):3413-22. PubMed ID: 22465746 [TBL] [Abstract][Full Text] [Related]
8. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens. Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452 [TBL] [Abstract][Full Text] [Related]
10. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102 [TBL] [Abstract][Full Text] [Related]
11. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus. Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate. Kim MC; Lee YN; Kim YJ; Choi HJ; Kim KH; Lee YJ; Kang SM Antiviral Res; 2017 Dec; 148():43-52. PubMed ID: 29107058 [TBL] [Abstract][Full Text] [Related]
13. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378 [TBL] [Abstract][Full Text] [Related]
14. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice. Inn KS; Lee GJ; Quan FS Immunol Invest; 2014; 43(3):236-54. PubMed ID: 24354853 [TBL] [Abstract][Full Text] [Related]
15. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Matassov D; Cupo A; Galarza JM Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114 [TBL] [Abstract][Full Text] [Related]
16. [Progress in development of influenza virus-like particles]. Ge SQ; Wang ZL Bing Du Xue Bao; 2013 Mar; 29(2):224-32. PubMed ID: 23757857 [TBL] [Abstract][Full Text] [Related]
17. Development of a dual-protective live attenuated vaccine against H5N1 and H9N2 avian influenza viruses by modifying the NS1 gene. Choi EH; Song MS; Park SJ; Pascua PN; Baek YH; Kwon HI; Kim EH; Kim S; Jang HK; Poo H; Kim CJ; Choi YK Arch Virol; 2015 Jul; 160(7):1729-40. PubMed ID: 25959557 [TBL] [Abstract][Full Text] [Related]
18. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. Nogales A; Baker SF; Ortiz-Riaño E; Dewhurst S; Topham DJ; Martínez-Sobrido L J Virol; 2014 Sep; 88(18):10525-40. PubMed ID: 24965472 [TBL] [Abstract][Full Text] [Related]
19. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Wei HJ; Chang W; Lin SC; Liu WC; Chang DK; Chong P; Wu SC Vaccine; 2011 Sep; 29(41):7163-72. PubMed ID: 21651946 [TBL] [Abstract][Full Text] [Related]
20. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Tao P; Luo M; Zhu D; Qu S; Yang Z; Gao M; Guo D; Pan Z Viral Immunol; 2009 Jul; 22(4):273-81. PubMed ID: 19594398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]